Related by context. All words. (Click for frequent words.) 78 DSMB 75 Committee IDMC 66 unblinded 66 multicenter Phase 65 DSMB recommended 65 phase IIb clinical 65 oral ridaforolimus 65 PRECISE Trial 64 LibiGel Phase III 64 phase IIb 64 ocrelizumab 64 Phase IIIb clinical 64 Phase 2b study 63 SYMMETRY trial 62 viral kinetic 62 APPRAISE 62 phase Ib 62 SUCCEED trial 62 phase IIb study 62 DASISION 62 senicapoc 62 midstage clinical 62 CALGB # [002] 62 Canvaxin 62 ENRICH trial 61 Phase IIb trials 61 forodesine 61 Phase III clinical 61 confirmatory Phase III 61 Dacogen injection 61 Phase Ib study 61 Phase 2a trial 61 unblind 61 EMPHASIS HF trial 61 Phase Ib clinical 61 CUSTOM III 61 Phase Ia 61 phase IIa 61 AVERROES 61 confirmatory clinical 61 PEARL SC 61 arzoxifene 61 vandetanib 60 interferon gamma 1b 60 pharmacokinetic PK 60 Intermezzo ® NDA 60 Phase IIb clinical 60 Phase Ib 60 placebo controlled Phase 60 maximally tolerated dose 60 NEBIDO 60 unblinding 60 REVLIMID lenalidomide 60 PEG SN# 60 IMPROVE IT 60 sNDA submission 60 TELCYTA 60 Alzhemed TM 60 multiple ascending dose 60 Phase 1b 60 placebo controlled clinical trials 60 phase IIb trial 60 MAGE A3 ASCI 60 ongoing Phase 1b 60 randomized Phase III 60 Phase 1b trial 60 Phase 2b kidney transplant 60 severe hypercholesterolemia 59 alvimopan 59 RSD# oral 59 AVADO 59 PROPEL trial 59 ACTEMRA TM 59 Phase IIb trial 59 GetGoal Phase III 59 muraglitazar 59 alvespimycin 59 Fablyn 59 Phase #b/#a 59 darusentan 59 albinterferon alfa 2b 59 SPARLON 59 QNEXA 59 figitumumab 59 dose cohort 59 HCV SPRINT 59 AIM HIGH 59 FOLOTYN ® 59 motesanib 59 dirucotide 59 SILENOR TM 59 BRIM3 59 Phase IIa trial 59 R# #mg BID 59 PROVENGE ® 59 ACTIVE W 59 GENASIS trial 59 Phase IIa clinical 59 Prostate AdenoCarcinoma Treatment 59 huC# DM4 59 nab paclitaxel 59 eniluracil 58 double blinded placebo 58 octreotide implant 58 Phase III pivotal 58 dosing cohorts 58 ASCEND HF 58 aflibercept 58 Fibrillex TM 58 motavizumab 58 pegloticase 58 elotuzumab 58 GLP toxicology studies 58 Plicera 58 AVASTIN 58 Prosaptide 58 PROMACTA 58 Phase #b/#a clinical 58 NP2 Enkephalin 58 baminercept 58 registrational trial 58 placebo controlled Phase III 58 multicenter Phase II 58 ZEGERID Chewable Tablets 58 dose escalation 58 romiplostim 58 anakinra 58 Phase III multicenter 58 rALLy trial 58 oral rivaroxaban 58 cangrelor 58 Asentar 58 EmbraceAC 58 Metabolic Drugs Advisory 58 confirmatory Phase 3 58 peginesatide 58 phase IIIb 58 TBC# 58 ZOLINZA 58 MEND CABG II 58 mcg dose 58 EDEMA3 58 daclizumab 58 deforolimus 58 Entereg 58 FDA Oncologic Drugs 58 Tarceva TM 58 dose escalation phase 58 clinical trial 58 NSABP C 58 SAR# [004] 58 multicenter Phase III 58 Ocrelizumab 58 Corlux 58 subcutaneous formulation 58 oral deforolimus 58 Phase 2b clinical 58 Phase #b/#a trial 58 phase 2a 58 Phase Ib II 58 Dose escalation 58 QLT# 58 MERLIN TIMI 58 Phase 2a 58 bevirimat Study 58 PIX# [002] 58 relapsed MCL 58 NDA submission 58 TRA 2P 58 PREZISTA r 58 GOUT 58 dose escalation Phase 58 HCV RESPOND 2 58 Prestara 58 docetaxel Taxotere R 58 ADVANCE PD 58 AIR CF1 58 phase Ib clinical 58 MADIT II 58 Proellex TM 57 Phase III confirmatory 57 PRIMO CABG 57 CEQ# 57 BLA filing 57 Genasense ® oblimersen 57 Sulonex 57 axitinib 57 dose dose escalation 57 Aurexis 57 Nexavar sorafenib 57 APEX PD 57 Phase IIb clinical trials 57 APEX AMI trial 57 PRISTIQ 57 Onrigin 57 Allovectin 7 ® 57 dose escalation trial 57 Aflibercept 57 lorvotuzumab mertansine 57 AVOREN 57 Phase IIIb study 57 ENDEAVOR IV 57 PRIMO CABG2 57 Phenoptin 57 Oncologic Drugs Advisory 57 randomized discontinuation trial 57 ongoing Phase IIIb 57 Phase III clinical trials 57 Phase 2a clinical 57 Inc. Nasdaq VVUS 57 albiglutide 57 crizotinib PF # 57 generation purine nucleoside 57 evaluating Actimmune 57 VIRAMUNE XR 57 HGS ETR2 57 Allovectin 7 57 registrational 57 dosing cohort 57 pertuzumab 57 TELINTRA 57 docetaxel chemotherapy 57 Phase IIa clinical trials 57 Phase 1a clinical 57 neratinib 57 eprodisate Fibrillex TM 57 Efficacy Results 57 pharmacokinetic PK study 57 ARCOXIA 57 midstage studies 57 antibody MAb 57 teduglutide 57 MIRCERA 57 Zerenex 57 Phase IIb III 57 brivaracetam 57 Cimzia TM 57 eprotirome 57 NSABP 57 randomized Phase 2b 57 RANK Ligand inhibitor 57 lomitapide 57 Xinlay 57 bile duct tumor 57 Fx #A 57 placebo controlled clinical 57 Tocosol Paclitaxel 57 ILLUMINATE 57 dose escalation clinical 57 velafermin belinostat 57 vismodegib 57 dalbavancin 57 Study GL# 57 Phase 1b clinical 57 Omigard 57 Telavancin 57 Traficet EN 57 Phase III metastatic melanoma 57 randomized Phase IIb 57 TOCOSOL Paclitaxel 57 Nasdaq MAPP 57 lucinactant 57 active comparator 57 IMPACT DCM 57 Xcytrin R 57 oral methylnaltrexone 57 Mylotarg 57 Aptivus ® 57 Egrifta 57 teriflunomide 57 randomized controlled clinical trials 57 AZILECT R 57 Kynapid 57 zalutumumab 57 BRIM2 57 Amrubicin 57 XL# SAR# 56 Revlimid lenalidomide 56 HGS# 56 ELND# 56 mertansine 56 pivotal Phase III 56 abatacept 56 Phase 2a clinical trials 56 MyVax personalized immunotherapy 56 SPIRIT FIRST 56 pharmacodynamics PD 56 ezogabine 56 PANVAC VF 56 trastuzumab DM1 56 PRT# 56 EchoCRT 56 Sibutramine Cardiovascular Outcomes 56 HuMax CD4 56 PDX pralatrexate 56 denufosol 56 Phase IIB 56 midstage trials 56 ASSERT trial 56 rNAPc2 56 Androxal TM 56 Hematide ™ 56 placebo controlled studies 56 metastatic castration resistant 56 metastatic HRPC 56 Raptiva ® 56 Inc. Nasdaq NEOL 56 pharmacokinetics PK 56 MIST II 56 velafermin 56 multicenter clinical 56 Phase 2b trial 56 Velcade bortezomib 56 randomized controlled Phase 56 CR# vcMMAE 56 blinded randomized placebo controlled 56 JAK inhibitor 56 Bicifadine 56 vosaroxin 56 tolevamer 56 FavId 56 phase IIa clinical 56 refractory CLL 56 Phase IIb 56 Initiate Phase 56 BioNumerik 56 Amigal 56 Phase #/#a 56 CHAMPION PCI 56 oxymorphone ER 56 Phase III placebo controlled 56 PRE SURGE 56 Nasdaq ONXX today 56 enzastaurin 56 Sprycel dasatinib 56 Nasdaq PGNX today 56 IIa trial 56 thorough QT 56 treatment naive genotype 56 Phase III LibiGel 56 supplemental Biologics License Application 56 Xelox 56 #D#C# 56 PROVENGE sipuleucel T 56 Phase 2b clinical trials 56 Phase IIa trials 56 iclaprim 56 HGS ETR1 56 ecallantide 56 cetrorelix pamoate 56 IMGN# 56 efficacy endpoints 56 recurrent glioblastoma multiforme 56 REVLIMID R 56 MEND CABG 56 Nabi HB Intravenous 56 INSPIRE Trial Phase III 56 aleglitazar 56 subcutaneous PRO 56 AVE# 56 bicifadine 56 posaconazole 56 TACI Ig 56 paliperidone palmitate 56 prospectively defined 56 investigational humanized monoclonal antibody 56 CINTREDEKIN BESUDOTOX 56 placebo controlled trials 56 Troxatyl 56 ENDEAVOR III 56 BAY #-# 56 Atrasentan 56 BCIRG 56 compound INCB# 56 Phase Ib clinical trials 56 BLA submission 56 CRMD# 56 evaluating tivozanib 56 reslizumab 56 Application BLA 56 romidepsin 56 CoFactor 56 Zalbin 56 ORAL Sync 56 randomized Phase 56 MAA submission 56 virus HCV protease inhibitor 56 vicriviroc 56 HCD# [002] 56 T Pred 56 COMFORT II 56 Pixuvri 56 APTIVUS 56 patients undergoing percutaneous 55 Tavocept 55 PRECISE trial 55 Silenor NDA 55 ponatinib 55 secondary efficacy endpoints 55 Vernakalant 55 FDA Endocrinologic 55 NATRECOR R 55 Zenvia ™ 55 Acetavance 55 ExTRACT TIMI 55 dose titration 55 trastuzumab DM1 T DM1 55 administered subcutaneously 55 temsirolimus 55 angiogenesis inhibitor 55 LibiGel ® testosterone gel 55 ThermoDox R 55 oral anticoagulant 55 Pivotal Phase III 55 bazedoxifene 55 rALLy clinical trial 55 sorafenib Nexavar 55 Heplisav 55 sodium Injection 55 GAMMAGARD 55 IL# PE#QQR 55 tremelimumab 55 ataluren 55 cetuximab Erbitux 55 TYGACIL 55 Pimavanserin 55 PSN# [002] 55 randomized blinded 55 FOLOTYN 55 ANTEGREN 55 glufosfamide 55 methylnaltrexone 55 valopicitabine 55 EMPOWER ™ 55 subcutaneously administered 55 vernakalant oral 55 NATRECOR ® 55 GVAX 55 telomerase inhibitor drug 55 GSK# [001] 55 Phase #/#a trial 55 dexpramipexole 55 tolerated dose MTD 55 RE LY 55 GRNVAC1 55 ruxolitinib 55 Viramidine 55 Clolar 55 refractory chronic lymphocytic 55 placebo controlled randomized 55 prospective randomized placebo 55 APTIVUS r 55 ganetespib 55 dacetuzumab 55 Pivotal Trial 55 Testosterone MDTS ® 55 clinical pharmacology studies 55 Sutent sunitinib malate 55 Randomized Phase 55 selective androgen receptor modulator 55 EDEMA4 55 fidaxomicin Phase 3 55 eliglustat tartrate 55 Telcyta 55 INCB# [001] 55 GED aPC 55 Genasense R oblimersen 55 granted Ortec 55 Lovaxin C 55 AQ4N 55 selective modulator 55 EURONEXT SAN 55 PNP inhibitor 55 JOULFERON 55 edoxaban 55 ULORIC 55 anticancer compound 55 tramiprosate ALZHEMED TM 55 Capesaris 55 AIR CF2 55 MAXY alpha 55 vidofludimus 55 registrational studies 55 apricitabine ATC 55 ISTODAX 55 randomized controlled multicenter 55 PFO migraine 55 Bezielle 55 noninferiority 55 lintuzumab SGN 55 PXD# 55 IgG1 monoclonal antibody 55 clevidipine 55 BR.# 55 Ambrisentan 55 AIMM trial 55 Veronate 55 Phase III trials 55 TASKi2 55 CLIRS trial 55 SPIRIVA HandiHaler 55 solanezumab 55 mapatumumab 55 Phase lll 55 Syncria 55 gadobutrol 55 PEG PAL 55 prospective multicenter 55 Maximum Tolerated Dose MTD 55 EVEREST II 55 Nasdaq GNTA 55 prGCD 55 ascending dose 55 mg administered orally 55 label multicenter 55 pivotal bioequivalence 55 REVIVE Diabetes 55 Alimta pemetrexed 55 ORMD 55 single ascending dose 55 ANCHOR trial 55 cardio renal 55 NVA# 55 STRIDE PD 55 Quinamed 55 Biologics License Application BLA 55 Trovax 55 GTC recombinant human 55 Zenpep 55 SCH # 55 oral cladribine 55 alogliptin 55 MADIT CRT 55 tramiprosate Alzhemed TM 55 Dasatinib 55 multicenter randomized double 55 pralatrexate 55 Ophena 54 PREOS 54 receptor tyrosine kinase inhibitor 54 peg IFN 54 DU #b 54 SILENOR 54 pivotal Phase 54 efalizumab 54 serum phosphorous 54 Tanespimycin 54 IDX# 54 TOLAMBA 54 talactoferrin 54 DEB# 54 PIX# trial 54 multicenter randomized placebo controlled 54 eprodisate KIACTA TM 54 ruboxistaurin 54 pomalidomide 54 FDA Advisory Panel 54 IND submission 54 LibiGel ® 54 investigational compounds 54 efficacy endpoint 54 dose escalation study 54 aripiprazole Abilify 54 NO# [002] 54 Entereg R 54 Rasilez Tekturna 54 Metabolic Drugs 54 pirfenidone 54 Annamycin 54 oral prodrug 54 double blinded randomized 54 riociguat 54 Amigal TM 54 trastuzumab emtansine T DM1 54 intravenous dosing 54 Telintra 54 lintuzumab 54 faropenem 54 dose regimens 54 preclinical efficacy 54 Thorough QT 54 RG# [001] 54 TAXUS IV 54 Clonicel 54 Alfimeprase 54 Nebido 54 CONSERV 54 antiplatelet agent 54 randomized multicenter 54 efficacy tolerability 54 Vidaza azacitidine 54 phase III isavuconazole 54 Torisel 54 Ixempra 54 LymphoStat B 54 rindopepimut 54 approvability 54 Viprinex 54 Multaq R 54 Hydroxyurea 54 zanolimumab 54 ridaforolimus 54 Genz # 54 Qnexa 54 Raptiva R 54 Ranolazine 54 Ophthalmic Drugs Advisory 54 MyVax 54 DAPT 54 HCV NS5B polymerase 54 teplizumab 54 GALNS 54 CIP ISOTRETINOIN 54 carcinogenicity study 54 XIENCE V Everolimus Eluting 54 IMPACT IMmunotherapy 54 candidate AQ4N 54 visilizumab 54 ixabepilone 54 APEX AMI 54 dirucotide MBP# 54 Psychopharmacologic Drugs Advisory 54 casopitant 54 HuMax EGFr 54 IMPACT DCM clinical 54 PF # [002] 54 LibiGel testosterone gel 54 Pivotal Clinical Trial 54 investigational antiplatelet agent 54 MEK inhibitor RDEA# 54 RE SURGE 54 RSR# 54 glatiramer acetate 54 Diamyd ® 54 LUX Lung 54 Phase III Clinical Trial 54 UPLYSO 54 Nplate 54 Pirfenidone 54 docetaxel Taxotere ® 54 apaziquone 54 CERVARIX 54 Soliris TM eculizumab 54 BRILINTA 54 Cethromycin 54 ALN VSP Phase 54 Phase III HEAT 54 null responder HCV 54 Inc. NASDAQ BPAX 54 Leukine 54 PegIntron 54 desvenlafaxine succinate 54 sitaxsentan 54 Pivotal Phase 54 taranabant 54 coadministration 54 Laquinimod 54 primary efficacy endpoints 54 GSK# [002] 54 safety tolerability pharmacokinetic 54 R rosiglitazone maleate 54 Xanafide 54 tanespimycin 54 velaglucerase alfa 54 Zoraxel 54 Nuvion 54 postmarketing surveillance 54 designated HVTN 54 Nasdaq CYCC Nasdaq CYCCP 54 ATACAND 54 PHX# 54 PARTNER Trial 54 Jevtana 54 methylnaltrexone bromide 54 Bonefos 54 mcg kg 54 atacicept 54 Zenvia Phase III 54 hGH CTP 54 Prospective Randomized 54 investigational compound 54 Certolizumab pegol 54 OvaRex ® MAb 54 MNTX 54 Horizant 54 Fodosine 54 ambrisentan 54 mg/m2 cohort 54 peg interferon 54 Adalimumab 54 LymphoStat B TM 54 Octreolin 54 Hyphanox 54 Phase IIIb 54 FAME Study 54 ICA # 54 label dose escalation 54 TASKi3 54 R sorafenib tablets 54 insulin detemir 54 rivaroxaban Xarelto 54 blinded randomized 54 investigational hepatitis B 54 initiate Phase IIb 54 PD LID 54 cutaneous T cell 54 PROSTVAC ® 54 dosage regimens 54 CERVARIX R 54 AVANDIA 54 REG1 54 Tolamba 54 eltrombopag 54 ATL# [001] 54 Dementia Related Psychosis 54 Nasdaq DVAX 54 EDARBI 54 TWYNSTA ® 54 LY# [003] 54 tolerability pharmacokinetics 54 custirsen 54 Pulminiq 54 RE LY ® 54 sunitinib 54 INCB# [002] 54 MKC# MT 53 Trizytek 53 pramlintide 53 AGILECT R 53 dimebon 53 Phase III Pivotal 53 PEGINTRON TM 53 Randomized Phase II 53 cell lymphoma CTCL 53 MGd 53 L MTP PE 53 ENESTnd Evaluating Nilotinib Efficacy 53 ARIKACE 53 NeuroFlo 53 plus prednisone 53 AZOR 53 RIO Lipids 53 ACTEMRA 53 Phase 1a 53 PrandiMet TM 53 budesonide foam 53 randomized multicenter Phase III 53 Medidur TM FA 53 bosutinib 53 acyclovir Lauriad R 53 nonclinical studies 53 Potiga 53 highly purified pasteurized 53 Aryplase 53 NOXAFIL Oral Suspension 53 evaluating mipomersen 53 NASDAQ GNTA 53 balsalazide tablet 53 NEO3 53 ELACYT 53 Neurodex 53 ofatumumab 53 liprotamase 53 ONGLYZA 53 regorafenib 53 AZD# 53 LEUKINE 53 #mg/m# [002] 53 mesylate tablets 53 Cycloset 53 pharmacokinetics pharmacodynamics 53 postoperative ileus POI 53 HORIZONS AMI trial 53 indiplon capsules 53 ToGA 53 hypoxia activated prodrug 53 lymphoma CTCL 53 AEG# 53 Initiates Phase II 53 relapsed MM 53 label multicenter Phase 53 Plenaxis TM 53 Carotid Revascularization Endarterectomy vs. 53 Stimuvax 53 Anturol TM 53 huN# DM1 53 EOquin 53 XL# XL# XL# XL# 53 pharmacodynamic effects 53 lixisenatide 53 LEXIVA r 53 CAMMS# 53 Arranon 53 anti arrhythmic 53 Zemplar Capsules 53 betrixaban 53 azacitidine 53 torezolid phosphate 53 picoplatin 53 nitazoxanide 53 mipomersen 53 NOXAFIL 53 Hematide ™ peginesatide 53 ATryn R 53 VIMOVO 53 prospective randomized multicenter 53 prucalopride 53 Reclast Aclasta 53 NV1FGF 53 lenalidomide Revlimid R 53 Genasense ® 53 Azedra 53 opioid induced bowel dysfunction 53 Maximum Tolerated Dose 53 REMICADE ® 53 Diamyd R 53 requiring Asthmatx 53 Certican 53 palifosfamide 53 TMC# C# 53 Q#IR 53 multicenter phase 53 lorcaserin Phase 53 bevacizumab Avastin 53 ospemifene 53 Celebrex celecoxib 53 Triolex 53 Endocrinologic 53 Ophena TM 53 blind randomized placebo 53 IMC A# 53 Orathecin 53 canakinumab 53 fostamatinib 53 THALOMID 53 CHAMPION PLATFORM 53 AIDAC 53 Aurora kinase inhibitor 53 Biologics Licensing 53 TYKERB 53 severe gastroparesis 53 CALGB 53 Panzem R 53 Phase Ib IIa 53 EOquin TM 53 cancer neuroendocrine tumor 53 iPrEx 53 tasocitinib 53 BLP# Liposome Vaccine 53 Excellarate TM 53 ISO Vorin TM 53 TKM ApoB 53 CCR5 antagonist 53 tesmilifene 53 Hepatocellular Carcinoma HCC 53 ancrod 53 Vivus Qnexa 53 dosing intervals 53 PrevOnco ™ 53 RELOVAIR ™ 53 bifeprunox 53 dronedarone 53 Drug Administration FDA Oncologic 53 Femara letrozole 53 Phase IIa 53 Dabigatran etexilate 53 clazosentan 53 Multiple Ascending Dose 53 Act PDUFA date 53 Teriflunomide 53 SIMPADICO 53 Orexigen Contrave 53 Augment Injectable 53 REALITY Trial 53 ONCONASE R 53 CIMZIA TM 53 Personalized Immunotherapy 53 Zavesca R 53 CATIE AD 53 L BLP# 53 ritonavir boosted 53 HoFH 53 Nasdaq VRTX 53 clinical trials 53 systemic anaplastic large 53 goserelin 53 fosbretabulin 53 PEGylated interferon beta 1a 53 initiate Phase 1b 53 LAF# 53 KRN# 53 imetelstat GRN#L 53 orBec 53 Biologic License Application BLA 53 ZYBRESTAT fosbretabulin 53 Zolinza 53 non inferiority 53 Marqibo 53 phase IIb III 53 KYNAPID 53 guanfacine extended release 53 arsenic trioxide injection 53 Phase III randomized 53 Avastin bevacizumab 53 midstage clinical trials 53 Ostarine 53 YONDELIS 53 APF# Phase 53 asymptomatic hyperuricemia 53 SinuNase TM 53 IV acetaminophen 53 olanzapine LAI 53 Tolvaptan 53 placebo controlled multicenter 53 adalimumab Humira 53 Eltrombopag 53 Edge STudy 53 JZP 53 PTK ZK 53 IPLEX 53 experimental hepatitis C 53 Biologics License Application 53 Fludara 53 SUPPRELIN R LA 53 lapatinib Tykerb 53 landmark ATHENA 53 PERSEUS clinical program 53 optimal dosing 53 Phase IIb Clinical Trial 53 Nasdaq OSCI 53 controlled multicenter 53 CAPACITY trials 53 IMA# 53 apricitabine 53 liver resection surgeries 53 OPT CHF 53 relapsed refractory multiple myeloma 53 Adentri 53 Zelrix 53 Initiates Phase III 53 BCR ABL inhibitor 53 Phase III psoriasis 53 Promacta 53 Phase IIB clinical 53 Kiacta 53 Cethrin 53 Combination REOLYSIN R 53 Folfox 53 Febuxostat 53 Junovan 53 omacetaxine mepesuccinate 53 XL# XL# XL# 53 ACOMPLIA R 53 multicenter placebo controlled 53 ASA# 53 CEL SCI Phase III 53 QNEXA ® 53 Vectibix panitumumab 53 GRAVITAS trial 53 octreotide acetate 53 AFRESA 53 investigational oral 53 Sebivo 53 LymphoStat B belimumab 53 mCRC patients 53 Phase III TRIST 53 Phase 1b clinical trials 53 ThermoDox ® clinical 53 assessing T DM1 53 NDA resubmission 53 Technosphere Insulin 53 mg kg dose 53 FDA Dermatologic 53 ORENCIA ® 53 ROCKET AF 53 Panzem R NCD 53 oral FTY# 53 Hedgehog Pathway Inhibitor 53 initiated Phase Ib 53 Cloretazine ® 53 Omnitarg 53 Avandia rosiglitazone 53 morphometric vertebral fractures 53 primary endpoint 53 boards IRBs 53 rhThrombin 53 RhuDex 53 INC# 53 induced macular edema 53 ADP receptor antagonist 52 TORISEL 52 s pill Qnexa 52 Neuvenge 52 IIa clinical trial 52 Cleviprex TM clevidipine 52 Hedgehog antagonist 52 Complete Response 52 Mipomersen 52 olaparib